Researchers investigated the associations between clinical characteristics of coronavirus disease 2019 (COVID-19) and immunoglobulin G (IgG) antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
In a recent study published in the journal Science, researchers at Yale University developed a novel coronavirus disease 2019 (COVID-19) vaccination strategy termed 'prime and spike' (P&S) that leveraged existing systemic immunity triggered by parenteral vaccination (prime) to boost immunity at the respiratory mucosa.
Researchers from the U.K. used data from clinical trials of the Oxford-AstraZeneca COVID-19 vaccine ChAdOx1 nCoV-19 to understand the genetic factors contributing to the individual variations in the antibody responses to the vaccine.